Press Release: New long-term Leqvio(R) -2-

generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Ray K, Troquoy R, Visseren F, et al. Efficacy and Safety Of Twice Yearly

Subcutaneous lnclisiran In Patients With High Cardiovascular Risk And

Elevated Low-density Lipoprotein Cholesterol Up To 4 Years: The ORION-3

Trial. American Heart Association (AHA) Scientific Sessions 2022.November

5-7, 2022. Chicago, IL.

2. Ray K, Roell P, Visseren F, et al. Long-term efficacy and safety of

inclisiran in patients with high cardiovascular risk and elevated LDL-C

(ORION 3): Results from the 4-year open-label extension of the ORION-1

trial. Data presented at the American Heart Association (AHA) Scientific

Sessions 2022 on November 7.

3. Ray K, Wright R, Kallend D, et al. Two Phase 3 Trials of Inclisiran in

Patients with Elevated LDL Cholesterol. N Engl J Med.

2020;382(16):1507--1519.

4. Raal F, Kallend D, Ray K, et al. Inclisiran for the Treatment of

Heterozygous Familial Hypercholesterolemia. N Engl J Med.

2020;382(16):1520--1530.

5. Goldstein JL, Brown MS. A Century of Cholesterol and Coronaries: from

Plaques to Genes to Statins. Cell. 2015;161(1):161--172.

6. Skålén K, Gustafsson M, Rydberg E, et al. Subendothelial

Retention of Atherogenic Lipoproteins in Early Atherosclerosis. Nature.

2002;417(6890):750--754.

7. Tabas I, Williams K, Borén J. Subendothelial Lipoprotein Retention

as the Initiating Process in Atherosclerosis: Update and Therapeutic

Implications. Circulation. 2007;116(16):1832--1844.

8. Ference B, Graham I, Tokgozoglu L, Catapano A. Impact of lipids on

Cardiovascular Health: JACC health promotion series. J Am Coll Cardiol.

2018;72(10):1141--1156.

9. Bruckert E, Parhofer K, Gonzalez-Juanatey J, et al. Proportion of

High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein

Cholesterol at Target According to European Guidelines: A Systematic

Review. Adv Ther. 2020;37(5):1724--1736.

10. Wong N, Young D, Zhao Y, et al. Prevalence of the American College of

Cardiology/American Heart Association statin eligibility groups, statin

use, and low-density lipoprotein cholesterol control in US adults using

the National Health and Nutrition Examination Survey 2011--2012. J Clin

Lipidol. 2016;10(5):1109--1118.

11. Ray K, Raal F, Kallend D, et al. Inclisiran and Cardiovascular Events: A

Prespecified Exploratory Analysis of Pooled Individual Participant Data

from Three Phase III Randomised Trials. Eur Heart J. 2022; ehac594.

12. ORION-1 (NCT02597127). Trial to Evaluate the Effect of ALN-PCSSC

Treatment on Low Density Lipoprotein Cholesterol (LDL-C). Available at:

https://clinicaltrials.gov/ct2/show/NCT02597127

13. World Health Organization (WHO). Cardiovascular diseases (CVDs).

Published June 2021. Accessed October 2022.

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-

(cvds)

14. European Society of Cardiology (ESC). Fighting Cardiovascular Disease --

a Blueprint for EU Action. Published June 2020. Accessed October 2022.

Available at

https://www.escardio.org/static-file/Escardio/Advocacy/Documents/2020%20ESC-EHN-blueprint_digital%20edition.pdf

15. Arnett D, Blumenthal R, Albert M, et al. 2019 ACC/AHA Guideline on the

Primary Prevention of Cardiovascular Disease: A Report of the American

College of Cardiology/American Heart Association Task Force on Clinical

Practice Guidelines. Circulation. 2019;140(11):e596-e646.

16. Expert Panel on Detection, Evaluation, and Treatment of High Blood

Cholesterol in Adults. Executive Summary of the Third Report of the

National Cholesterol Education Program (NCEP) Expert Panel on Detection,

Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult

Treatment Panel III). JAMA. 2001; ;285(19):2486-97

17. World Health Organization (WHO). Fact sheet. Non-communicable diseases.

Published June 2018. Accessed October 2022. Available at:

https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

18. World Health Organization (WHO). Cardiovascular diseases: Avoiding heart

attacks and strokes. Published September 2015. Accessed October 2022.

Available at:

https://www.who.int/news-room/questions-and-answers/item/cardiovascular-diseases-avoiding-heart-attacks-and-strokes

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Mary Carmichael +1 862 200 8344

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

November 07, 2022 16:24 ET (21:24 GMT)